Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 32, 2015, Pages 9990-9995

  Wang, Zhijie ^a   Shen, Zhirong ^b,c   Li, Zhenxiang ^a,d   Duan, Jianchun ^a   Fu, Shuai ^a   Liu, Zhentao ^a   Bai, Hua ^a   Zhang, Zemin ^e   Zhao, Jun ^a   Wang, Xiaodong ^b,c   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^e PEKING UNIVERSITY   (China)

Author keywords

Bone morphogenetic proteins; Drug resistance; Epidermal growth factor receptor tyrosine kinase inhibitor; Lung squamous cell carcinoma

Indexed keywords

6 [4 (1 PIPERAZINYL)PHENYL] 3 (4 QUINOLINYL)PYRAZOLO[1,5 A]PYRIMIDINE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GW 788388; LY 2109761; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN; THYROID TRANSCRIPTION FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; S6 KINASE; SMAD PROTEIN;

ARTICLE; CANCER SCREENING; CELL VIABILITY; CHINESE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; GENE MAPPING; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RNA SEQUENCE; SQUAMOUS CELL LUNG CARCINOMA; ADENOCARCINOMA; ADULT; AGED; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NON SMALL CELL LUNG CANCER; NUDE MOUSE; REPRODUCIBILITY; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE, NUDE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84938917325     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510837112     Document Type: Article

References (32)

1. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18(6): 1059-1068.
2. Travis WD, Brambilla E, Riely GJ (2013) New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol 31(8): 992-1001.
3. Sequist LV, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75): 75ra26.
4. Mok TS, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10): 947-957.
5. Maemondo M, et al.; North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25): 2380-2388.
6. Mitsudomi T, et al.; West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11(2): 121-128.
7. Rosell R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3): 239-246.
8. Zhou C, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8): 735-742.
9. Kwak EL, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18): 1693-1703.
10. Shaw AT, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26): 4247-4253.
11. Shukuya T, et al. (2011) Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. Cancer Sci 102(5): 1032-1037.
12. Network TCGAR; Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417): 519-525.
13. Kim Y, et al. (2014) Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 32(2): 121-128.
14. Hata A, et al. (2013) How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR genesensitive mutations? J Thorac Oncol 8(1): 89-95.
15. Rekhtman N, et al. (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: Lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18(4): 1167-1176.
16. Roggli VL, et al. (1985) Lung cancer heterogeneity: A blinded and randomized study of 100 consecutive cases. Hum Pathol 16(6): 569-579.
17. Zheng C, Sun YH, Ye XL, Chen HQ, Ji HB (2011) Establishment and characterization of primary lung cancer cell lines from Chinese population. Acta Pharmacol Sin 32(3): 385-392.
18. Bean J, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52): 20932-20937.
19. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1): 21-35.
20. Langenfeld E, Hong CC, Lanke G, Langenfeld J (2013) Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines. PLoS One 8(4): E61256.
21. Attisano L, Wrana JL (2002) Signal transduction by the TGF-beta superfamily. Science 296(5573): 1646-1647.
22. Kretzschmar M, Liu F, Hata A, Doody J, Massagué J (1997) The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev 11(8): 984-995.
23. Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511): 543-550.
24. Choi YL, et al. (2013) EGFR mutation testing in patients with advanced non-small cell lung cancer: A comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One 8(2): E56011.
25. Marchetti A, et al. (2005) EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23(4): 857-865.
26. Bai H, et al. (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-smallcell lung cancer. J Clin Oncol 27(16): 2653-2659.
27. Tanaka T, et al. (2010) Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126(3): 651-655.
28. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12(2): 175-180.
29. Tseng JS, et al. (2012) Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer 77(1): 128-133.
30. Miyamae Y, et al. (2011) Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 25(4): 921-928.
31. Serizawa M, Takahashi T, Yamamoto N, Koh Y (2013) Combined treatment with erlotinib and a transforming growth factor-beta type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. J Thorac Oncol 8(3): 259-269.
32. Fei ZH, Yao CY, Yang XL, Huang XE, Ma SL (2013) Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev 14(9): 5293-5299.